BullFrog AI stock soars 101% after landmark Pfizer partnership for depression drug discovery
Shares of BullFrog AI surged by more than 101% after the company announced a partnership with Pfizer, the world's largest pharmaceutical firm. The deal, revealed on 25 March 2026, focuses on accelerating drug discovery for major depressive disorder (MDD) using BullFrog's AI-driven platform. Investors also pushed the company's warrant ticker, BFRGW, up by over 35% in the same session. The collaboration centres on BullFrog AI's bfLEAP technology, which helps identify and rank drug targets for MDD. Pfizer gains exclusive rights to one target candidate as part of the agreement. BullFrog's platform stands out by integrating multi-omics data and graph neural networks, claiming 30% higher predictive accuracy in psychiatric drug response modelling than competitors like Insilico Medicine or Recursion Pharmaceuticals.
BullFrog's suite includes three key tools: **bfLEAP** for target discovery, **bfPREP** for data processing, and **bfARENAS** for portfolio optimisation. The company's CEO, Vin Singh, called the Pfizer deal a major endorsement of its AI capabilities. He highlighted the platform's ability to handle 'multimodal biological complexity at scale', simplifying early-stage drug development. The MDD treatment market surpassed $8 billion in 2025 and is forecast to hit $11 billion by 2032. BullFrog AI's technology uses causal network inference to help researchers navigate vast biological datasets. With this partnership, the company aims to build on its track record in target discovery and secure further commercial deals.
The partnership grants Pfizer access to BullFrog's advanced AI tools for MDD research. The stock surge reflects investor confidence in the company's approach. BullFrog AI now looks to expand its collaborations, leveraging its platform's proven performance in drug development.
